Advertisement
Screener

ROIVANT SCIENCES LTD. (ROIV) Noncontrolling Interest, Increase from Subsidiary Equity Issuance

ROIVANT SCIENCES LTD. Noncontrolling Interest, Increase from Subsidiary Equity Issuance

ROIVANT SCIENCES LTD. (ROIV) reported Noncontrolling Interest, Increase from Subsidiary Equity Issuance of $87.50 million for the 12-month period ending 2023-03-31, per its 10-K filed 2025-05-29.

Financial Statements › Shareholders' Equity › Noncontrolling Interest Items

us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance · last filed 2025-05-29

  • ROIVANT SCIENCES LTD. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2022-12-31 was $87.50M.
  • ROIVANT SCIENCES LTD. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2021-09-30 was $70.00M.
  • ROIVANT SCIENCES LTD. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2023 was $87.50M, a 25.00% increase from fiscal 2022.
  • ROIVANT SCIENCES LTD. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2022 was $70.00M.
Period endNoncontrolling Interest, Increase from Subsidiary Equity Issuance 3 monthNoncontrolling Interest, Increase from Subsidiary Equity Issuance 12 month
2023-03-31$87.50M
10-K · filed 2025-05-29
2022-12-31$87.50M
10-Q · filed 2024-02-13
2022-03-31$70.00M
10-K · filed 2023-06-28
2021-09-30$70.00M
10-Q · filed 2023-02-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Zoetis Inc. (ZTS)United States$29.045B11.38
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10